Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Revive Therapeutics Ltd
(OP:
RVVTF
)
0.0100
-0.0009 (-8.26%)
Streaming Delayed Price
Updated: 3:55 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Revive Therapeutics Ltd
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder
March 28, 2023
First subject enrolled and initial top-line results expected in Q3-2023
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
March 20, 2023
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Provides Update From Type C Meeting with FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
March 08, 2023
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Psyched: 12 States Discuss Legalization Bills, Ceremonies For Veterans With TBI, Ketamine And MDMA Fast-Tracks & More
February 13, 2023
Psychedelics Legislation: The Latest On Hawaii, Virginia, Missouri & More
Via
Benzinga
MDMA News: Optimi's New Drug Now Available, Revive Advances Transdermal Patch Evaluations
February 06, 2023
Considering MDMA will likely be the first psychedelic to receive FDA approval for psychotherapeutic use to treat serious mental health conditions such as PTSD, seve
Via
Benzinga
Revive Therapeutics Secures MDMA Supply from PharmAla Biotech for MDMA Transdermal Patch Development
February 06, 2023
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
PharmaTher Holdings Nabs New Orphan Drug Status, Discusses Further Fast-Track, Partners For MDMA Patch
February 03, 2023
Ketamine products manufacturer PharmaTher Holdings Ltd. (OTCQB: PHRRF) had lots happening this past week. Here are the company's top three news items.
Via
Benzinga
Revive Therapeutics Enters into Research Collaboration Agreement with PharmaTher for Development of MDMA Transdermal Patch
February 03, 2023
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Submits Updated Briefing Package in Support of Upcoming Type C Meeting Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
January 19, 2023
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Psyched: Psychedelics In Davos, Prince Harry In The 90s, Cathie Wood's Latest Moves And More
January 17, 2023
Psychedelics Take Center Stage In Davos Psychedelics will lead the conversation inside the Davos House of Health for a second year in a row this January.
Via
Benzinga
Revive Therapeutics To Submit Updated Briefing Package in Support of Upcoming Type C Meeting Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
January 12, 2023
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Psychedelics Company Revive Raises $3.2M To Target Infectious Diseases, Disorders
January 12, 2023
Life sciences company Revive Therapeutics Ltd. (OTCQB: RVVTF) raised funds to treat infectious diseases and rare disorders, including meth addiction.<
Via
Benzinga
Revive Therapeutics Ltd. Closes $4.3 Million Offering
January 12, 2023
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Announces Publication Showing Bucillamine’s Potential Impact on COVID-19 Omicron Variants
January 09, 2023
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
January 05, 2023
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Announces Submission of Type C Meeting Request to FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
December 22, 2022
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Psyched: First Ayahuasca Pill Created, Psychedelics Legalization Predicted, UK's Research Support And More
December 19, 2022
Ayahuasca Pill Is Officially Here, Filament CEO Discusses Future Plans The first medical-grade drug candidate of the psychedelic ayahuasca is being developed.
Via
Benzinga
Psyence, Revive Therapeutics Ink Private Placements: Capital To Support Drug Trials
December 16, 2022
Life sciences biotech Psyence Group Inc. (OTCQB: PSYGF) has closed the second tranche of its previously announced private placement of up to $2.2 million (CA$3 million).
Via
Benzinga
Revive Therapeutics Ltd. Expands Life Offering to Quebec
December 15, 2022
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics To Raise Up To $5M Via Private Placement
December 01, 2022
REVIVE THERAPEUTICS LTD. (OTCQB: RVVTF) (CSE:RVV) announced that it is arranging a private placement of a minimum of $3 million and up to $5 million of units, at a price of $0.15 per unit;.
Via
Benzinga
Revive Therapeutics Ltd. Announces Offering of Up to $5 Million
November 30, 2022
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Psychedelic Stock Gainers And Losers From November 30, 2022
November 30, 2022
Via
Benzinga
Revive Therapeutics, Seelos Therapeutics Among Top Psychedelic Movers Of Today
November 29, 2022
Via
Benzinga
Revive Therapeutics, Compass Pathways Among Top Psychedelic Movers Of Today
November 28, 2022
Via
Benzinga
Psychedelic Stock Gainers And Losers From November 25, 2022
November 25, 2022
Via
Benzinga
Psychedelic Stock Gainers And Losers From November 24, 2022
November 24, 2022
Via
Benzinga
Revive Therapeutics Announces Update for Type C Meeting to Discuss Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
November 24, 2022
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Psychedelic Stock Gainers And Losers From November 23, 2022
November 23, 2022
Via
Benzinga
Psychedelic Stock Gainers And Losers From November 22, 2022
November 22, 2022
Via
Benzinga
Revive Therapeutics Announces FDA Recommendation for Type C Meeting to Discuss Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
November 22, 2022
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.